Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cholinergic/dopaminergic control of attentional processes in schizophrenia
2005-004186-41Phase 2Terminated
- Sponsor
- RWTH Aachen University
- Start
- Jan 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of biperiden in schizophrenia (3 arms), sponsored by RWTH Aachen University. Primary endpoints: Primary completion of planned cohort recruitment and Change in cerebral D2-like dopamine receptor availability after biperiden. Started Jan 2006; status: terminated.
02
Drugs
biperiden
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2005-004186-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004186-41.